|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
|
Apr 2023
|
The Oncologist
|
myelodysplastic syndromes (MDS)
|
|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
|
Apr 2023
|
The Oncologist
|
myelodysplastic syndromes (MDS)
|
|
What causes aplastic anaemia?
|
Apr 2023
|
Leukemia
|
aplastic anemia
|
|
Newly revised 2023 MDS response criteria
|
Apr 2023
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
|
Apr 2023
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
|
Apr 2023
|
Blood
|
aplastic anemia
|
|
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care
|
Apr 2023
|
Transplantation and Cellular Therapy
|
myelodysplastic syndromes (MDS)
|
|
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases
|
Apr 2023
|
Internal and Emergency Medicine
|
myelodysplastic syndromes (MDS)
|
|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
|
Apr 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
|
Apr 2023
|
Current Hematologic Malignancy Reports
|
myelodysplastic syndromes (MDS)
|
